drug
vericiguat
Marketedupdated 4mo agoby Merck Sharp & Dohme LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying vericiguat
- phase3Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- —An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
- —A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
- —An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
- —An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
- phase2Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome
- phase2Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
- phase3A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 21, 2029
~2.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Nov 26, 2032compositionUS 9604948
- Nov 26, 2032compositionUS 9604948
- Nov 26, 2032compositionUS 9604948
- May 19, 2031compositionUS 107368964.7y
- May 19, 2031compositionUS 107368964.7y
- May 19, 2031compositionUS 107368964.7y
- May 19, 2031method-of-use (U-3062)US 114396424.7y
- May 19, 2031method-of-use (U-3062)US 114396424.7y
- May 19, 2031method-of-use (U-3062)US 114396424.7y
- May 19, 2031compositionUS 84206564.7y
- May 19, 2031compositionUS 84206564.7y
- May 19, 2031compositionUS 84206564.7y
- May 19, 2031method-of-use (U-3062)US 89213774.7y
- May 19, 2031method-of-use (U-3062)US 89213774.7y
- May 19, 2031method-of-use (U-3062)US 89213774.7y
- May 19, 2031method-of-use (U-3062)US 99934764.7y
- May 19, 2031method-of-use (U-3062)US 99934764.7y
- May 19, 2031method-of-use (U-3062)US 99934764.7y
FDA exclusivities (6)
- Jan 21, 2029D-198New Indication (3y)2.4y
- Jan 21, 2029D-198New Indication (3y)2.4y
- Jan 21, 2029D-198New Indication (3y)2.4y
- Jan 19, 2026NCENew Chemical Entity (5y)
- Jan 19, 2026NCENew Chemical Entity (5y)
- Jan 19, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that